DLBCL, NOS GENETIC SUBTYPES
Clinical trials for DLBCL, NOS GENETIC SUBTYPES explained in plain language.
Never miss a new study
Get alerted when new DLBCL, NOS GENETIC SUBTYPES trials appear
Sign up with your email to follow new studies for DLBCL, NOS GENETIC SUBTYPES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on tough lymphoma
Disease control OngoingThis early-phase trial tests a new type of CAR T-cell therapy for adults with B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to better target and kill cancer cells. The study aims to find the safest dose a…
Matched conditions: DLBCL, NOS GENETIC SUBTYPES
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo aims to boost CAR T-Cell success in tough lymphomas
Disease control OngoingThis phase 2 study tests whether adding the drug acalabrutinib to the CAR T-cell therapy lisocabtagene maraleucel (liso-cel) can improve outcomes for people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 28 adults will receive acalabruti…
Matched conditions: DLBCL, NOS GENETIC SUBTYPES
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC